Background: Dyspepsia and headache frequently co-exist, but the clinical implication of this association is uncertain. We planned to examine the prevalence and impact of dyspepsia in adults with headache.
Methods: A cross-sectional study was conducted in a secondary care setting. Clinical, psychological and health-related quality of life (HRQOL) data were compared between subjects with headache and controls (non-headache subjects). The impact of dyspepsia was analysed further in subjects with headache alone.
Results: 280 subjects (93 cases with headache and 187 matched controls) were recruited. The following baseline characteristics of subjects were as follows: mean age 45.0 ± 17.3 years, 57.0% females and ethnic distribution-Malaysian = 45 (48.4%), Chinese n = 24 (25.8%) and Indians n = 24 (25.8%). Headache sub-types among cases with headache were as follows: tension-type headache (TTH) n = 53 (57.0%) and migraine n = 40 (43.0%). Dyspepsia was more prevalent in cases with headache compared to controls (25.8% vs 12.8%, p = 0.011), and headache was independently associated with dyspepsia (OR 2.75, 95% CI 1.39-5.43). Among cases with headache, there was a trend towards a higher prevalence of dyspepsia in those with migraine (27.5%) compared to TTH (24.5%). Subjects with headache and dyspepsia, compared to those with headache alone, had a greater severity of headache symptoms (63.67 ± 22.85 mm vs 51.20 ± 24.0 mm VAS, p = 0.029). Overall HRQOL scores were lower in headache subjects with dyspepsia (EQ-5D summary score 0.82 ± 0.18 vs 0.90 ± 0.16, p = 0.037 and EQ-5D VAS 62.08 ± 17.50 mm vs 72.62 ± 18.85 mm, p = 0.018), compared to those without dyspepsia.
Conclusion: Dyspepsia is associated with more severe headache symptoms and results in a lower HRQOL in patients with headache.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309562 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115838 | PLOS |
J Headache Pain
January 2025
Chulalongkorn Headache and Orofacial Pain (CHOP) Service and Research Group, Chulalongkorn University, Bangkok, Thailand.
J Headache Pain
January 2025
Department of Neurology, Koventhospital Barmherzige Brüder, Linz, Austria.
Background: Proton pump inhibitor (PPI) drugs are widely used and are among the most significant achievements of modern pharmacology. Their primary purpose is treating and preventing gastric acid-related disorders. Migraine and PPI intake are prevalent, and many people are affected by both.
View Article and Find Full Text PDFCurr Pain Headache Rep
January 2025
Faculty of Health Sciences, Universidade da Beira Interior, Av. Infante D. Henrique, Covilhã, 6200-506, Portugal.
Introduction: Central Post-Stroke Pain (CPSP) is a debilitating condition with a significant prevalence in stroke survivors. Set apart by its refractory to treatment neuropathic pain, it appears to arise from lesions in the spino-thalamo-cortical pathways, particularly in the thalamus. Despite advances in neuroimaging techniques, the pathophysiology of CPSP remains poorly understood, with limited diagnostic criteria and therapeutic approaches.
View Article and Find Full Text PDFExpert Rev Neurother
January 2025
Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Introduction: When a first anti-CGRP monoclonal antibody (anti-CGRP mAb) fails, switching to a different anti-CGRP mAb is an option often considered, despite this approach is not yet systemically studied.
Methods: We present the findings of a systematic review conducted according to the PRISMA recommendations on published studies - of any design - investigating the clinical outcomes after switching for any reason to different anti-CGRP mAbs.
Results: The literature search retrieved 76 records, while 19 papers were eventually reviewed.
AJNR Am J Neuroradiol
January 2025
From the Department of Radiology and Imaging, Hospital for Special Surgery, New York, New York
CT-guided injection and radiofrequency ablation (RFA) of the C2 dorsal root ganglion (DRG) is a safe and effective treatment for cervicogenic headache arising from C1-C2 joint arthritis. The C2 nerve root is unique in that it lacks a motor component; RFA can be performed with pain relief in exchange for occipital numbness. This video article outlines the imaging anatomy and technical considerations of this procedure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!